Ted

“I just had some questions with respect to what still had to be done for the SPL or SNDA, considering, obviously, Selimixor is already approved in multiple myeloma, you know, how much of the filings already done and is there anything you'll say you need to compile on the clinical side?”

“That's really helpful, and I appreciate how you laid it out of the call earlier. Thanks very much.”

“Great. thank you very much and um appreciate all the color um on the um priorities to get approval launch and then the lawsuit i have a question just sort of what the depths are from here with respect to the lawsuit i know you mentioned that you had requested um an expedited um lawsuit or I forget the exact word you…”

“And just maybe digging a little bit deeper in terms of the external partnering, Should we be more thinking complementary technology, then, from your comments earlier, Yvonne, whether that be delivery types or other RNA mechanisms?”